Cosmo Pharmaceuticals NV

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
N/A
SEDOL
BYYLS68
CIK
N/A
cosmopharma.com
LEI: 724500OX0EBQRYTVV639
©
New: Infographics X-Lab
FIGI: BBG00CWWYK50
COPN
Cosmo Pharmaceuticals NV
GICS: 35202010 · Sektor: EQTY · Sub-Sektor: -
AI
PROFILER
NAME
Cosmo Pharmaceuticals NV
ISIN
NL0011832936
TICKER
COPN
MIC
XSWX
REUTERS
COPN.S
BLOOMBERG
COPN SW
F&G: 59
6.401,61 S&P · 16,78 Vola-Index · 119.204,11 BTC · 1,16455 EURUSD
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von Newsfile Corp. bereitgestellt.
Fr., 08.08.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda (TSE: 4502) (NYSE: TAK), to produce Mesalazine MMX 1200 mg (marketed as Liald...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 23.07.2025       Cosmo Pharmaceuticals
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Do., 17.07.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - July 17, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with H...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 16.07.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - July 16, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact. ...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Di., 01.07.2025       Cosmo Pharmaceuticals
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation.Dublin, Ireland--(Newsfile Corp. - July 1, 2025) - Cosmo N.V. (SIX: COPN), a global leader in AI-driven h...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 25.06.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Di., 24.06.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that in July 2025, it will initiate their first usability study of a medical device software application connecting the Medtronic GI Genius™ intelligent endoscopy module, an AI-powered platform for gastrointestinal e...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Fr., 30.05.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of sha...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mo., 05.05.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Fr., 02.05.2025       Cosmo Pharmaceuticals
NL0011832936

Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification[1] for Cerebro, a Real-Time AI-powered guide for complete Esophagogastroduodenoscopy (EGD) procedures. As one of the first Computer-Assisted Qu...
Zur Nachricht
Cosmo Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

BARRISTA SMART * AD

P R O D U C T   S U G G E S T I O N S